Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema

DOI Web Site Web Site 17 References
  • Orui Satoshi
    Portfolio & Product Strategy Department, Torii Pharmaceutical CO., LTD.
  • Nozue Haruka
    Portfolio & Product Strategy Department, Torii Pharmaceutical CO., LTD.
  • Kobayashi Satoko
    Medical Affairs Department, Torii Pharmaceutical CO., LTD.
  • Fujioka Masaki
    Medical Affairs Department, Torii Pharmaceutical CO., LTD.
  • Maekawa Yuriko
    Medical Affairs Department, Torii Pharmaceutical CO., LTD.

Bibliographic Information

Other Title
  • 遺伝性血管性浮腫の急性発作抑制薬ベロトラルスタット塩酸塩（オラデオカプセル150 mg）の薬理学的特徴及び臨床試験成績
  • イデンセイ ケッカンセイ フシュ ノ キュウセイ ホッサ ヨクセイヤク ベロトラルスタット エンサンエン(オラデオカプセル 150mg)ノ ヤクリガクテキ トクチョウ オヨビ リンショウ シケン セイセキ

Search this article

Abstract

<p>Hereditary angioedema (HAE) is a rare disease that causes serious health problem and affects on quality of life for patient due to recurrent episodes of angioedema in various body such as the skin, larynx, digestive tract, and limbs. Many HAE patients have deficiency or dysfunction of C1 inhibitor, impaired regulation of plasma kallikrein activity and overproduction of bradykinin, resulting in leading to episodes of increased capillary hyper permeability and angioedema. Therapy of HAE consists of on-demand treatment for acute attack and prophylactic treatment by suppressing the onset of acute attack in the short and long term. However, no drug has been approved for long-term prophylaxis in Japan. Berotralstat hydrochloride (ORLADEYO Capsules 150 mg) is an oral, selective plasma kallikrein inhibitor approved for the suppression of the onset of acute attacks in HAE in Japan in January 2021. Preclinical studies demonstrated that Berotralstat is a potent and highly specific inhibitor of human plasma kallikrein activity. Berotralstat suppressed bradykinin production in the HUVEC system. Clinical studies demonstrated that oral administration of Berotralstat to HAE type I or type II patients at a dose of 150 mg once daily showed a reduction of HAE attack rate and clinically significant change in angioedema quality of life score. The most common side effect was gastrointestinal symptoms. In conclusion, preclinical and clinical data indicated that Berotralstat is an effective treatment for long-term prophylactic treatment by suppressing the onset of acute attack in HAE patient and is considered to be a useful treatment option for patients.</p>

Journal

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top